Global Finance News
30 Jan 2026, 14:32
AstraZeneca has agreed a major strategic collaboration with CSPC Pharmaceutical Group to expand its pipeline in obesity and type 2 diabetes, securing access to eight next-generation programmes and advanced drug-discovery technologies.
Under the agreement, AstraZeneca will obtain exclusive global rights outside China to CSPC’s once-monthly injectable weight management portfolio, including a clinical-ready asset, SYH2082, a long-acting GLP-1/GIP dual agonist set to enter Phase I trials, along with three additional preclinical candidates. The collaboration also gives AstraZeneca access to CSPC’s AI-driven peptide discovery platform and its proprietary LiquidGel monthly dosing technology, aimed at improving treatment adherence and convenience.
AstraZeneca will pay CSPC an upfront $1.2 billion, with potential development and regulatory milestones of up to $3.5 billion, plus sales milestones and tiered royalties. CSPC will advance the initial programmes through Phase I, after which AstraZeneca will lead further development and commercialisation outside China, while CSPC retains rights in China and selected territories.
The deal strengthens AstraZeneca’s weight management portfolio alongside existing assets such as elecoglipron and several injectable metabolic therapies, reflecting the company’s ambition to address obesity as a chronic, multifactorial disease with more convenient and scalable treatment options.
Under the agreement, AstraZeneca will obtain exclusive global rights outside China to CSPC’s once-monthly injectable weight management portfolio, including a clinical-ready asset, SYH2082, a long-acting GLP-1/GIP dual agonist set to enter Phase I trials, along with three additional preclinical candidates. The collaboration also gives AstraZeneca access to CSPC’s AI-driven peptide discovery platform and its proprietary LiquidGel monthly dosing technology, aimed at improving treatment adherence and convenience.
AstraZeneca will pay CSPC an upfront $1.2 billion, with potential development and regulatory milestones of up to $3.5 billion, plus sales milestones and tiered royalties. CSPC will advance the initial programmes through Phase I, after which AstraZeneca will lead further development and commercialisation outside China, while CSPC retains rights in China and selected territories.
The deal strengthens AstraZeneca’s weight management portfolio alongside existing assets such as elecoglipron and several injectable metabolic therapies, reflecting the company’s ambition to address obesity as a chronic, multifactorial disease with more convenient and scalable treatment options.